Table 1.
Baseline characteristics for DPT-1 and TN-07 participants who had a paired IVGTT and OGTT within 30 days before study randomization
| Baseline characteristics | DPT-1 (N = 194) | TN-07 (N = 292) | P valuea | |
|---|---|---|---|---|
| Age, y | ||||
| Mean (SD) | 15.1 (10.0) | 9.4 (6.1) | <0.0001 | |
| Median [Q1, Q3] | 11.8 [8.7, 17.2] | 8.1 [5.5, 12.2] | ||
| BMI percentileb | ||||
| Mean (SD) | 52.8 (31.0) | 59.5 (28.6) | 0.0259 | |
| Median [Q1, Q3] | 57.8 [24.8, 79.8] | 63.1 [36.8, 84.8] | ||
| Missing | 28 | 0 | ||
| Sex, n (%) | ||||
| Female | 100 (51.6) | 115 (39.4) | 0.0082 | |
| Male | 94 (48.5) | 177 (60.6) | ||
| Race, n (%) | ||||
| White | 176 (91.7) | 264 (96.4) | 0.0301 | |
| Non-White | 16 (8.3) | 10 (3.7) | ||
| Unknown | 2 | 18 | ||
| Relationship to proband, n (%) | ||||
| First degree | 177 (91.2) | 263 (90.1) | 0.6665 | |
| Second degree | 17 (8.8) | 29 (9.9) | ||
| HLA DR3 or DR4, n (%) | ||||
| Present | 155 (80.7) | 245 (84.2) | 0.3235 | |
| Absent | 37 (19.3) | 46 (15.8) | ||
| Unknown | 2 | 1 | ||
| Duration between IVGTT and OGTT, d | ||||
| Mean (SD) | 15.7 (10.8) | 21.3 (7.6) | <0.0001 | |
| Median [Q1, Q3] | 20.0 [3.0, 26.0] | 23.0 [17.5, 28.0] | ||
| T1D diagnosis reported within 5 y, n (%) | ||||
| Yes | 80 (41.2) | 84 (28.8) | ||
| No | 114 (58.8) | 208 (71.2) | ||
| Follow-up for T1D, y | ||||
| Median (range) | 4.7 (0.0-7.2) | 5.1 (0.0-11.5) |
Abbreviations: BMI, body mass index; DPT-1, Diabetes Prevention Trial-Type 1 Diabetes; IVGTT, intravenous glucose tolerance test; OGTT, oral glucose tolerance test; T1D, type 1 diabetes; TN-07, Type 1 Diabetes TrialNet “Oral Insulin for Prevention of Diabetes in Relatives at Risk for T1D.”
a Kruskal-Wallis test for continuous variables and χ2 test or Fisher exact test for categorical variables.
b For participants older than 20 years of age, BMI percentile values for age 20 years were applied.